Literature DB >> 23817368

Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.

James S Lewis1, Nathan P Wiederhold, Brian L Wickes, Thomas F Patterson, James H Jorgensen.   

Abstract

We report a case of Candida glabrata candidemia that developed resistance to micafungin within 8 days of initiation of therapy in a patient without previous echinocandin exposure or other known risk factors for clinical or microbiological failure. Pre- and postresistant isolates were confirmed to be isogenic, and sequencing of hot spots known to confer echinocandin resistance revealed a phenylalanine deletion at codon 659 within FKS2.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23817368      PMCID： PMC3754289          DOI： 10.1128/AAC.01144-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

2.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

3.  Identification of pathogenic yeasts of the imperfect genus Candida by polymerase chain reaction fingerprinting.

Authors:  W Meyer; G N Latouche; H M Daniel; M Thanos; T G Mitchell; D Yarrow; G Schönian; T C Sorrell
Journal:  Electrophoresis       Date:  1997-08       Impact factor: 3.535

4.  Molecular genotyping of Candida species with special respect to Candida (Torulopsis) glabrata strains by arbitrarily primed PCR.

Authors:  K Becker; D Badehorn; S Deiwick; G Peters; W Fegeler
Journal:  J Med Microbiol       Date:  2000-06       Impact factor: 2.472

5.  Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.

Authors:  David R Andes; Nasia Safdar; John W Baddley; Geoffrey Playford; Annette C Reboli; John H Rex; Jack D Sobel; Peter G Pappas; Bart Jan Kullberg
Journal:  Clin Infect Dis       Date:  2012-03-12       Impact factor: 9.079

6.  Genotyping and drug resistance profile of Candida spp. in recurrent and one-off vaginitis, and high association of non-albicans species with non-pregnant status.

Authors:  Pei Pei Chong; Siti Rohani Abdul Hadi; Yee Lean Lee; Chin Lee Phan; Boon Chong Tan; Kee Peng Ng; Heng Fong Seow
Journal:  Infect Genet Evol       Date:  2007-01-16       Impact factor: 3.342

7.  Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

Authors:  George R Thompson; Nathan P Wiederhold; Ana C Vallor; Nyria C Villareal; James S Lewis; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

8.  Identification of Candida spp. by randomly amplified polymorphic DNA analysis and differentiation between Candida albicans and Candida dubliniensis by direct PCR methods.

Authors:  Consuelo Bautista-Muñoz; Xavier M Boldo; Lourdes Villa-Tanaca; César Hernández-Rodríguez
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

9.  Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Cassaundra L Updike; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079
View more
  43 in total

1.  Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.

Authors:  Rasmus Hare Jensen; Ulrik Stenz Justesen; Annika Rewes; David S Perlin; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 2.  The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases.

Authors:  Ilan S Schwartz; Thomas F Patterson
Journal:  Curr Infect Dis Rep       Date:  2018-02-05       Impact factor: 3.725

3.  Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility.

Authors:  M Martí-Carrizosa; F Sánchez-Reus; F March; E Cantón; P Coll
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

Review 4.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

5.  Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance.

Authors:  Chayanika Biswas; Sharon C-A Chen; Catriona Halliday; Elena Martinez; Rebecca J Rockett; Qinning Wang; Verlaine J Timms; Rajat Dhakal; Rosemarie Sadsad; Karina J Kennedy; Geoffrey Playford; Deborah J Marriott; Monica A Slavin; Tania C Sorrell; Vitali Sintchenko
Journal:  J Vis Exp       Date:  2017-12-28       Impact factor: 1.355

6.  Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy.

Authors:  Ziauddin Khan; Suhail Ahmad; Eiman Mokaddas; Jacques F Meis; Leena Joseph; Aneesa Abdullah; Sandhya Vayalil
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

7.  Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.

Authors:  Laura Bedin Denardi; Jéssica Tairine Keller; Vanessa Oliveira; Débora Alves Nunes Mario; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Mycopathologia       Date:  2017-05-10       Impact factor: 2.574

8.  ERG6 and ERG2 Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical Candida glabrata Isolates in Kuwait.

Authors:  Suhail Ahmad; Leena Joseph; Josie E Parker; Mohammad Asadzadeh; Steven L Kelly; Jacques F Meis; Ziauddin Khan
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

9.  Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.

Authors:  Fernando César Bizerra; Cristina Jimenez-Ortigosa; Ana Carolina R Souza; Giovanni Luis Breda; Flávio Queiroz-Telles; David S Perlin; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

10.  Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.

Authors:  A Forastiero; V Garcia-Gil; O Rivero-Menendez; R Garcia-Rubio; M C Monteiro; A Alastruey-Izquierdo; R Jordan; I Agorio; E Mellado
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.